Feasibility of the Reality PAWS Program for Children in Isolation

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age8-21
SponsorChildren's Hospital Colorado

About this trial

The goal of this clinical trial is to learn if a mixed reality program, Reality PAWS, delivered on a Meta Quest 3 VR headset, is a feasible intervention for pediatric patients in isolation. It will also evaluate the safety of the program and its effect on pain, anxiety, and loneliness. The main questions the study aims to answer are:

What is the feasibility of utilizing Reality PAWS MR as a substitute for in-person dog therapy for children under isolation precautions? Are patients compliant with using Reality PAWS MR? What are the interventional outcomes of Reality PAWS MR?

Participants will:

Wear a Meta Quest 3 VR headset with the Reality PAWS program. Interact with the program. Answer surveys regarding demographics, anxiety, pain, loneliness, sickness, perceived exertion, and immersion in the program.

Eligibility criteria

Qualifiers

Children 8 to 21 years old admitted to Children's Hospital Colorado or Children's Hospital Los Angeles

Children who are English-speaking (legal guardian may be English-speaking or Spanish-speaking)

Children within the normal range of development will be recruited for this study.

Disqualifiers

Traumatic brain injury, neurological disorders, neurodevelopmental issues, or other neurological disorders and comorbidities that may confound study outcomes and administration of the study protocol and metrics (e.g., visual field disturbances, frequent nausea/ vomiting, not medically stable, intellectual disability)

Children with visual, auditory, or tactile deficits that would interfere with the ability to complete the experimental tasks

Children with a history of seizure disorder

Children currently sick with flu-like symptoms or experiencing a headache or earache

Trial design

Treatments tested in this trial

  • Reality PAWS Program via Meta Quest 3 VR

Treatment groups

50 Participants
are divided into 1 treatment group

Sponsors and collaborators

Children's Hospital Colorado

Lead sponsor

Children's Hospital Los Angeles

Collaborator